GE HealthCare Technologies Inc.

ticker: GEHC step: 01 generated: 2026-05-13 source: quick-research

GE HealthCare Technologies Inc. (GEHC) — Business Overview

Business Description

GE HealthCare Technologies (NASDAQ: GEHC) is one of the world's largest medical technology and digital solutions companies, spun off from General Electric in January 2023. The company develops, manufactures, and sells medical imaging equipment, ultrasound systems, patient monitoring solutions, and pharmaceutical diagnostic agents, serving hospitals, imaging centers, and healthcare systems in over 160 countries. With approximately $20B in annual revenue and 51,000+ employees, GEHC is a leading provider of CT scanners, MRI systems, X-ray equipment, PET/SPECT imaging, and AI-powered clinical decision tools, with the FDA's largest portfolio of AI-enabled device authorizations (80+ clearances, targeting 200+ by 2027).

Revenue Model

Revenue is split approximately 65% products and 35% services. Products include imaging equipment (one-time capital sale to hospitals), contrast agents/radiopharmaceuticals (recurring consumables), and increasingly software (transitioning toward subscription). Services include multi-year equipment maintenance contracts, software licenses, and cloud-based digital health solutions. The company is targeting a significant shift toward recurring software and services revenue, with a goal to triple cloud-based solutions and grow digital revenue ~50% by expanding subscription offerings.

Products & Services

• Imaging: CT scanners (Revolution series), MRI systems (Signa series), X-ray, Photonova Spectra photon-counting CT (FDA review pending, 2026 approval expected)
• Ultrasound: Vscan Air (handheld), Venue, Logiq — cardiac, women's health, general imaging
• Advanced Visualization Solutions (AVS): Edison AI platform — FDA-cleared AI tools for radiology workflow, triage, and reporting
• Patient Care Solutions (PCS): Carescape monitoring systems, anesthesia machines, infant care, respiratory care
• Pharmaceutical Diagnostics (PDx): Omnipaque/Visipaque contrast agents, Flyrcado (cardiac PET agent — ~220 weekly doses/week, $500M+ revenue target by 2028), Vizamyl (Alzheimer's amyloid imaging)
• Intelerad (acquired Nov 2025, $2.3B): Cloud-based enterprise imaging software (PACS/VNA) — adds $270M recurring software revenue at 30%+ EBITDA margin

Customer Base & Go-to-Market

Hospital systems, academic medical centers, imaging centers, and specialty clinics worldwide. Government/public healthcare systems (UK NHS, European systems) are significant customers. China historically ~15–20% of revenue. Sold through a direct enterprise sales force (large systems), distributor networks (smaller facilities), and service contracts managed by field engineers. Strong GPO and IDN relationships in the U.S.

Competitive Position

GEHC competes primarily with Siemens Healthineers and Philips in medical imaging, and with Mindray, Canon, and Samsung in ultrasound. GEHC holds leading positions in CT (#1–2 globally), MRI (#2), and X-ray. The AI-enabled device pipeline — largest portfolio of FDA AI clearances in medical imaging — is a key differentiator as hospitals move toward AI-assisted radiology workflows. The NVIDIA partnership (announced GTC 2025) targets autonomous imaging systems (X-ray, ultrasound) with physical AI integration, a multi-year competitive positioning move.

Key Facts

• Founded: 2023 (spun off from GE; predecessor operations date to 1896 with GE's X-ray business)
• Headquarters: Chicago, Illinois
• Employees: ~51,000
• Exchange: NASDAQ
• Sector / Industry: Health Care / Health Care Equipment & Supplies
• Market Cap: ~$18B

ticker: GEHC step: 04 generated: 2026-05-13 source: quick-research

GE HealthCare Technologies Inc. (GEHC) — Financial Snapshot

Income Statement Summary

FY2024 organic revenue growth was modest (~1%) on a reported basis as China weakness and PDx supplier disruption offset growth elsewhere. Adjusted EPS grew 22% to $4.59 in FY2025 (fiscal year reported in early 2026), absorbing $0.43/share in tariff headwinds. Adjusted EBIT margins expanded steadily from ~14.5% (FY2022) to ~17–18% (FY2024–2025).

Cash Flow & Balance Sheet (FY2024)

Key Ratios (approximate)

• P/E: ~15–18x (adjusted) | EV/EBITDA: ~12x | FCF Yield: ~8–9%
• Revenue Growth (FY2024): ~+1% reported (+4% organic ex-China)
• Adjusted EPS (FY2025): $4.59 (+22% YoY, absorbing $0.43 tariff drag)
• Backlog: Record $21.8B (book-to-bill ratio 1.07x at end of 2025)

Growth Profile

GEHC is in the early innings of its post-spin-off strategic transformation — shifting from a GE division focused on hardware to a standalone company emphasizing AI software, cloud services, and recurring revenue. Reported revenue has been flat (~$19.6–19.7B) due to China headwinds and macro-driven capital equipment spending softness, but organic growth ex-China is tracking 4–6%. Adjusted EPS has grown 20%+ YoY as margins expand (Heartbeat lean operating system, mix shift to software/services). The record $21.8B backlog and 1.07x book-to-bill provide solid revenue visibility.

Forward Estimates

• FY2025 Revenue: ~$20.0–20.5B (Q4 FY2025 revenue up 7.1% YoY)
• FY2026 Adjusted EPS Guidance: $4.95–$5.15 (8–12% growth; tariffs guided to "neutral to positive" vs. $0.43 headwind in FY2025)
• FY2026 China Guidance: Anticipated decline — remains a headwind
• Intelerad contribution: ~$270M recurring revenue at 30%+ adjusted EBITDA margin
• Analyst consensus: 14 of 20 analysts Buy/Outperform; median price target $95, implying ~29% upside

ticker: GEHC step: 12 generated: 2026-05-13 source: quick-research

GE HealthCare Technologies Inc. (GEHC) — Investment Catalysts & Risks

Bull Case Drivers

1. AI-Enabled Imaging Supercycle + World's Largest FDA AI Portfolio — GEHC holds the most FDA AI-enabled device authorizations of any medical imaging company (80+ clearances, targeting 200+ by 2027). As hospitals accelerate adoption of AI-assisted radiology workflows — automated triage, AI-powered reporting, dose optimization — GEHC's Edison AI platform is positioned as the software layer on top of its dominant CT/MRI/X-ray hardware installed base. The NVIDIA partnership (GTC 2025) targets autonomous imaging — X-ray and ultrasound systems that operate with minimal human intervention — which represents a step-change in imaging efficiency. If AI-enabled premium features drive average system ASP up 15–20% and support subscription software revenue alongside hardware, GEHC's margin profile could improve significantly above current ~17–18% adjusted EBIT margins.

2. Photon-Counting CT + Flyrcado PET Agent = Two Major Revenue Inflection Points — The Photonova Spectra photon-counting CT scanner — expected FDA approval in 2026 — represents the most significant CT technology advance in decades, offering spectral imaging capability at standard dose levels previously impossible with energy-integrating detectors. Photon-counting CT commands pricing premiums of $500K–$1M+ over conventional CT, and early clinical demand is strong. Simultaneously, Flyrcado (flurpiridaz cardiac PET agent) — hitting 220 weekly doses/week in early 2026 — is targeting $500M+ in annual revenue by end-2028, with the cardiac PET market highly underpenetrated relative to clinical need. Two major product cycle drivers simultaneously is unusual even for large medtech companies.

3. Record $21.8B Backlog Provides Revenue Visibility Across 2026–2027 — GEHC exited 2025 with a record $21.8B order backlog and a book-to-bill ratio of 1.07x — meaning it is booking more orders than shipping, building future revenue visibility. Capital equipment orders from hospital systems typically have 6–18 month fulfillment timelines, providing meaningful revenue predictability. The Intelerad acquisition (closed late 2025, $2.3B) adds $270M in high-margin recurring software revenue and positions GEHC as a full-stack enterprise imaging solution (hardware + AI + cloud PACS/VNA). If China stabilizes in 2027 and tariff headwinds diminish, backlog-driven revenue could support 5–7% organic growth with margin expansion.

Bear Case Risks

1. China Revenue Decline Is Structural, Not Cyclical — GEHC management explicitly guided for "a decline in China in 2026." China historically represented ~15–20% of GEHC revenue, but anti-corruption campaigns, domestic equipment procurement preferences (Beijing favoring domestic champions like Mindray, United Imaging), and geopolitical tensions have created structural headwinds. If China continues declining rather than stabilizing, the rest of the business needs to grow 7–8%+ just to keep total revenue flat. A prolonged China deterioration would also compress margins (China was a high-margin market) and potentially trigger further analyst estimate cuts.

2. Tariff Exposure and Supply Chain Vulnerability — Patient Care Solutions revenue fell 6.5% with segment EBIT collapsing 79.8% in Q4 2025, partially driven by tariff impacts and input cost inflation ("significant increases in memory chips, oil, and freight costs"). A PDx supplier issue disrupted pharmaceutical diagnostics revenue in 2024. While management claims tariffs are now "neutral to positive" to 2026, any tariff escalation (particularly on Chinese-made components or U.S. exports to China) could re-introduce the $0.43/share headwind that depressed FY2025 EPS. The Patient Care Solutions segment's near-term earnings power is uncertain.

3. Post-Spin Execution Risk and Intelerad Dilution — GEHC is only 2+ years into operating as a standalone company, having spent its entire prior existence as a GE division. Management is simultaneously running a $20B business, executing digital transformation, integrating Intelerad, managing China exposure, and navigating tariff volatility — significant organizational complexity for a company still building its standalone operating muscle. A guidance cut in April 2026 sent the stock down 13% in a single session, demonstrating that execution missteps carry outsized market impact. Intelerad dilution and integration costs will weigh on FY2026 earnings, and the $2.3B debt addition reduces financial flexibility.

Upcoming Events

• Q2 2026 Earnings (July 2026): Tracking China revenue trajectory, Photonova CT order momentum, Flyrcado dose/week ramp, and Intelerad integration progress
• Photonova Spectra FDA Approval (expected 2026): Potential catalyst — first major photon-counting CT approval from GEHC; commercial launch timing is key
• Flyrcado Revenue Ramp: Weekly dose tracking (~220 doses/week early 2026) vs. path to $500M+ by 2028; CMS reimbursement expansion is critical
• FY2026 EPS ($4.95–$5.15): Quarterly tracking — tariff mitigation and Intelerad ramp are swing factors

Analyst Sentiment

Broadly bullish on the long-term thesis: 14 of 20 analysts rate Buy/Outperform with a median price target of $95 (~29% upside from recent depressed levels after the April 2026 guidance cut). The consensus view is that GEHC's product supercycle (Photonova, Flyrcado), AI leadership (80+ FDA clearances, NVIDIA partnership), and record backlog justify a patient bull thesis. The near-term bear case is China + tariff + PCS weakness creating another guidance cut. The stock's 23% decline from highs and 13% single-day drop create a better risk/reward entry point for investors who believe the long-term AI imaging and pharmaceutical diagnostics thesis is intact.

Research Date

Generated: 2026-05-13